Firms, funds, people, portfolio companies and transactions from sworn filings and cited announcements, kept as a graph with a date and a source on every edge. Reported gross assets are never fund size, regulatory AUM is never dry powder, and a deal value prints only when someone disclosed it.

The names on this page are hidden. Create a free account and they fill in. No card, and every figure, date and source on this page is public either way.

Transactions / L• C•••••

ARCHIMED Diagnostics acquires Stago, a global leader in blood coagulation analysis

Platform acquisitionannouncedannounced Apr 29, 2026Fact
What happened
Target
L• C•••••
Platform
not an add-on on record
Control
Control
Share acquired
unknown
Industry
unknown
Target location
unknown
Seller kind
unknown
Rollover
unknown
Values, only where disclosed
Enterprise value
Not disclosed
Purchase price
Not disclosed
Equity value
Not disclosed
Target revenue
Not disclosed
Target EBITDA
Not disclosed
Multiple
Not disclosed
Parties and roles
2 named
Buy side
  • A•••••••Sponsorconfirmed
    “With offices in Europe, North America and Asia, ARCHIMED is a leading investment firm focused exclusively on healthcare industries.”
Side not stated
  • L• C•••••Targetconfirmed
    “ARCHIMED Diagnostics – the Diagnostics team of global private equity healthcare specialist ARCHIMED – has purchased alongside global investment group L• C••••• (formerly CDPQ), Stago, a world leader for the analysis of blood coagulation issues (hemostasis).”
Evidence
“ARCHIMED Diagnostics – the Diagnostics team of global private equity healthcare specialist ARCHIMED – has purchased alongside global investment group L• C••••• (formerly CDPQ), Stago, a world leader for the analysis of blood coagulation issues (hemostasis).”
Press release wires (PR Newswire, GlobeNewswire, Business Wire public pages and RSS)confidence 80%recorded Sep 15, 2026
ARCHIMED Diagnostics acquires Stago, a global leader in blood coagulation analysis | Private Equity Intelligence | DFX